Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy

American Journal of Roentgenology

Volumn 197, Issue 2, 2011, Pages

  O'Regan, Kevin N ^a   Jagannathan, Jyothipriya P ^a   Ramaiya, Nikhil ^a   Hodi, F Stephen ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Adverse drug effects; Immune response criteria; Ipilimumab; Melanoma; Oncologic imaging; Therapy

Indexed keywords

INFLIXIMAB; IPILIMUMAB;

ARTICLE; CANCER IMMUNOTHERAPY; COLITIS; DERMATITIS; ENTEROCOLITIS; HEPATITIS; HUMAN; HYPOPHYSITIS; IMAGE ANALYSIS; IMMUNE RESPONSE; MELANOMA; MYOPATHY; NEPHRITIS; OUTCOME ASSESSMENT; PANCREATITIS; PRIORITY JOURNAL; RADIOLOGY; SARCOIDOSIS;

ANTIBODIES, MONOCLONAL; DRUG TOXICITY; HUMANS; IMMUNOTHERAPY; MELANOMA; NEOPLASM STAGING; SKIN NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79960725786     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.10.6032     Document Type: Article

References (15)

1. O'Day SJ, Maio M, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010; 21:1712-1717
2. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723
3. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-214 (Pubitemid 11167383)
4. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216
5. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247
6. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15:7412-7420
7. Hoos A, Eggermont A, Janetzki S, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010; 102:1388-1397
8. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 2009; 58:823-830
9. Hunter G, Voll C, Robinson CA. Autoimmune inflammatory myopathy after treatment with ipilimumab. Can J Neurol Sci 2009; 36:518-520
10. Fadel F, El Karoui K, Knebelman B. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 2009; 361:211-212
11. Dillard T, Yedinak CG, Alumkal J, Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer sub-types. Pituitary 2010; 13:29-38
12. Eckert A, Schoeffler A, Dalle S, Phan A, Kiakouama L, Thomas L. Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. Dermatology 2009; 218:69-70
13. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2008; 24:2283-2289
14. Minor D, Chin K, Kashani-Sabet M. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. Cancer BiotherRadiopharm 2009; 24:321-325
15. Blansfield J, Beck K, Tran K, et al. Cytotoxic Tlymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 2005; 28:593-598 (Pubitemid 41533093)